Equity and dividends
As per December 31st 2013, the company reported on equity of NOK 77 million. On February 11th 2014, the settlement for the purchase of Vitasynth Ltd was finalized through an issue of 2 336 000 NattoPharma shares to the seller Novel Nutrition Network Ltd for the remaining 66 % ownership together with a cash payment of Euro 175 000. As per May 9th 2014, a share issue of NOK 1 742 739 was registered through the issuance of 580 913 new shares each with a face value of NOK 3 per share. The total number of shares issued as per May 9th is 12 619 822 each with a face value of NOK 3 and the total share capital is NOK 37.8 million.
The Board of Directors continuously assesses the working capital and investment capital needed to meet future growth, especially within the field of pharma, and has considered this to be more important than paying dividends. However, a policy of not paying dividends has not been adopted by the Board.
No dividends have been paid to the Company’s shareholders for the period 2004 - 2013.